{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:29:17Z","timestamp":1790814557666,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1124\/jpet.123.001609","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T21:50:11Z","timestamp":1681249811000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis"],"prefix":"10.1016","volume":"386","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-9172","authenticated-orcid":false,"given":"Hidetaka","family":"Hiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Arichika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Haruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001609_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1164\/rccm.201301-0021PP","article-title":"Phosphodiesterase-4 inhibitor therapy for lung diseases","volume":"188","author":"Begh\u00e8","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/jpet.123.001609_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.123.001609_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40272-013-0013-9","article-title":"Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations","volume":"15","author":"Carr","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1124\/jpet.123.001609_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","article-title":"A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1124\/jpet.123.001609_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu Rev Biochem"},{"issue":"Suppl 63","key":"10.1124\/jpet.123.001609_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2133.148.s63.1.x","article-title":"International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies","volume":"148","author":"Ellis","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.123.001609_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s13555-020-00389-5","article-title":"Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis","volume":"10","author":"Fahrbach","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1124\/jpet.123.001609_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/all.12112","article-title":"Characterization of different courses of atopic dermatitis in adolescent and adult patients","volume":"68","author":"Garmhausen","year":"2013","journal-title":"Allergy"},{"key":"10.1124\/jpet.123.001609_bib9","first-page":"147","article-title":"Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD","volume":"4","author":"Giembycz","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.123.001609_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2133.2002.04894.x","article-title":"Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis","volume":"147","author":"Griffiths","year":"2002","journal-title":"Br J Dermatol"},{"issue":"1, Suppl","key":"10.1124\/jpet.123.001609_bib11","doi-asserted-by":"crossref","first-page":"161s","DOI":"10.1111\/1523-1747.ep12276359","article-title":"Immunopharmacology of the atopic diseases","volume":"85","author":"Hanifin","year":"1985","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.123.001609_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/1523-1747.ep12297888","article-title":"Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis","volume":"107","author":"Hanifin","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.123.001609_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-2007-1014599","article-title":"Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine","volume":"22","author":"Hebenstreit","year":"1989","journal-title":"Pharmacopsychiatry"},{"key":"10.1124\/jpet.123.001609_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1124\/jpet.123.001609_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaad.2017.09.067","article-title":"Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: a multicenter retrospective study","volume":"78","author":"Ighani","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1124\/jpet.123.001609_bib16","doi-asserted-by":"crossref","first-page":"7628","DOI":"10.1073\/pnas.122041599","article-title":"Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-\u03b1 responses","volume":"99","author":"Jin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.123.001609_bib17","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.175.3.1523","article-title":"Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages","volume":"175","author":"Jin","year":"2005","journal-title":"J Immunol"},{"key":"10.1124\/jpet.123.001609_bib18","first-page":"197","article-title":"Phosphodiesterase 4 and its inhibitors in inflammatory diseases","volume":"35","author":"Jin","year":"2012","journal-title":"Chang Gung Med J"},{"key":"10.1124\/jpet.123.001609_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/1523-1747.ep12325538","article-title":"Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice","volume":"105","author":"Kitagaki","year":"1995","journal-title":"J Invest Dermatol"},{"key":"10.1124\/jpet.123.001609_bib20","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.4049\/jimmunol.159.5.2484","article-title":"Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile","volume":"159","author":"Kitagaki","year":"1997","journal-title":"J Immunol"},{"key":"10.1124\/jpet.123.001609_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001609_bib22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.123.001609_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0026-895X(24)23155-2","article-title":"Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes","volume":"55","author":"Ma","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.123.001609_bib24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/sj.bjp.0702911","article-title":"Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B","volume":"128","author":"Manning","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001609_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic treatment of adult atopic dermatitis: a review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1124\/jpet.123.001609_bib26","first-page":"403","article-title":"Adult atopic dermatitis: a review","volume":"151","author":"Napolitano","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1124\/jpet.123.001609_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000484407","article-title":"Emerging treatment options in atopic dermatitis: Topical therapies","volume":"233","author":"Nygaard","year":"2017","journal-title":"Dermatology"},{"key":"10.1124\/jpet.123.001609_bib28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0891-0618(00)00097-1","article-title":"Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography: comparison with monkey and rat brain","volume":"20","author":"P\u00e9rez-Torres","year":"2000","journal-title":"J Chem Neuroanat"},{"key":"10.1124\/jpet.123.001609_bib29","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.4049\/jimmunol.178.8.4820","article-title":"Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D","volume":"178","author":"Peter","year":"2007","journal-title":"J Immunol"},{"key":"10.1124\/jpet.123.001609_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI0215506","article-title":"Deletion of phosphodiesterase 4D in mice shortens \u03b1(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis","volume":"110","author":"Robichaud","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.123.001609_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial","volume":"186","author":"Saeki","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1124\/jpet.123.001609_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial","volume":"86","author":"Saeki","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1124\/jpet.123.001609_bib33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/1346-8138.14979","article-title":"Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study","volume":"46","author":"Saeki","year":"2019","journal-title":"J Dermatol"},{"key":"10.1124\/jpet.123.001609_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jps.2600800203","article-title":"Species differences in percutaneous absorption of nicorandil","volume":"80","author":"Sato","year":"1991","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.001609_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40268-019-00284-1","article-title":"Apremilast normalizes gene expression of inflammatory mediators in human keratinocytes and reduces antigen-induced atopic dermatitis in mice","volume":"19","author":"Schafer","year":"2019","journal-title":"Drugs R D"},{"key":"10.1124\/jpet.123.001609_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000029928","article-title":"The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations--an overview","volume":"13","author":"Simon","year":"2000","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"10.1124\/jpet.123.001609_bib37","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2165\/00003495-200363230-00002","article-title":"Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease","volume":"63","author":"Spina","year":"2003","journal-title":"Drugs"},{"key":"10.1124\/jpet.123.001609_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0006-2952(99)00346-9","article-title":"Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity","volume":"59","author":"Sudo","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.123.001609_bib39","first-page":"69","article-title":"Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme","volume":"10","author":"Thompson","year":"1979","journal-title":"Adv Cyclic Nucleotide Res"},{"key":"10.1124\/jpet.123.001609_bib40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase isozymes: molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524170450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:29:34Z","timestamp":1739971774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524170450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0022356524170450"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001609","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}